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Abstract
Background: Patients with persistent atrial fibrillation (AF) can be managed with either rhythm
or rate control strategy. The restoration and maintenance of the sinus rhythm is not superior to the
rate control regarding the total mortality and the rate of thromboembolic complications. Data
concerning the effect of these strategies on left ventricular morphology and function is missing. The
objective of our prospective randomised multicenter study in patients with persistent AF was to
evaluate the effect of these two approaches on left ventricular morphology and function.
Methods and Results: The study group consisted of 205 patients (F/M 71/134; mean age
60.8 ± 11.2 years), including 101 patients randomized to the rate control approach (Group I)
and 104 patients randomized to sinus rhythm (SR) restoration with DC cardioversion and
subsequent antiarrhythmic drug treatment (Group II). Mean duration of AF was 231.8 ±
± 112.4 days. At the end of follow-up (12 months), SR was present in 64% of patients in Group II.
Echocardiographic examination was performed at a baseline and at 2 and 12 months. The
comparison of the left ventricular end-diastolic diameter revealed no difference within and
between groups (50.8 ± 5.6 mm vs. 52.2 mm ± 6.8 mm at a baseline and 50.0 ± 6.0 vs. 52.0 ±
± 7.4 mm at 12 months, respectively). Overall, the fractional shortening of the left ventricle increased
during the follow-up. Thus, the initial significant difference between groups (32.8 ± 6.6% vs. 29.9 ±
± 6.9%, p < 0.005) became insignificant at 12 months (35.6 ± 7.4% vs. 31.3 ± 7.3%).
Conclusions: We found no significant difference regarding the left ventricular morphology
and function between the rate and rhythm control strategies in patients with persistent AF.
(Folia Cardiol. 2006; 13: 331–337)
atrial fibrillation, left ventricular function, rhythm control, rate control,
echocardiography
Editorial p. 272
332
Folia Cardiol. 2006, Vol. 13, No. 4
www.fc.viamedica.pl
Introduction
Impaired left ventricular systolic function seen
in atrial fibrillation (AF) seems to result from three
major causes. The atrial arrhythmia inevitably leads
to the loss of mechanical atrial function, adversely
affecting left ventricular (LV) end-diastolic filling.
In addition, abnormally fast ventricular rate in AF
may have an adverse effect on the contractility, par-
ticularly in patients with underlying LV damage [1].
Finally, there is data suggesting the significant ef-
fect of the variable duration of ventricular diastolic
filling on ventricular systolic function, independent
of the lack of atrial contribution in diastolic filling
and increased ventricular rate [2, 3]. These mecha-
nisms lead to the decrease of systolic function by
approximately 5% to 20% during AF, and the re-
storation of the sinus rhythm (SR) should have an
opposite effect [4]. Unlike the short-term effects of
AF on ventricular function, however, the long-term
effects are more difficult to predict. Chronic AF,
particularly if associated with inadequately control-
led ventricular rate, may lead to progressive LV
systolic dysfunction and dilatation [5]. On the other
hand, the negative inotropic effect of chronically
administered antiarrhythmic drugs may adversely
effect LV systolic function following SR restoration [6].
Although AF is a relatively common significant
arrhythmia, available data regarding the effect of SR
restoration on LV function is based on only a few
small observational studies. In particular, no stu-
dies have been performed to evaluate the long-term
effects of rhythm versus rate control approach on
LV function. Recently published AFFIRM and
RACE trials did not confirm the superiority of SR
restoration and the maintenance in terms of total
mortality and the rate of thromboembolic compli-
cations [7, 8]. However, no data from these studies
is available on the effect of rhythm versus rate con-
trol approach on LV systolic function.
The objective of this prospective multicenter
study was to compare LV morphology and systolic
function in patients with persistent AF randomized
to rhythm versus rate control approach. This ana-
lysis was performed as a part of the HOT CAFE
trial, the main findings of which were published
previously [9].
Methods
Basic concepts
How To Treat Chronic Atrial Fibrillation (HOT
CAFE) trial was an open prospective multicenter
study performed in 6 cardiological centers
(Katedra i Klinika Chorób Wewnętrznych i Kardiologii
I Wydziału Lekarskiego Akademii Medycznej w War-
szawie, Katedra i Klinika Chorób Wewnętrznych i
 Nadciśnienia Tętniczego I Wydziału Lekarskiego
Akademii Medycznej w Warszawie, Oddział Kardio-
logiczny Szpitala Wojewódzkiego w Siedlcach, Od-
dział Wewnętrzny Szpitala w Milanówku, Oddział
Kardiologiczny Szpitala Wojewódzkiego w Rado-
miu, Świętokrzyskie Centrum Kardiologiczne
w Kielcach). The study was initiated in March 1997,
randomization was continued until December 2000,
and last follow-up visits were performed in Decem-
ber 2001.
The study was approved by the local ethics
committees in participating centers. All patients
gave written informed consent for the participation
in the study.
Inclusion criteria
Patients aged 50–75 years were eligible for the
study if they had persistent, symptomatic AF of
£ 2 years of duration, with the removable or control-
lable cause of the arrhythmia and no contraindica-
tions to cardioversion and anticoagulation. The ar-
rhythmia could be related to ischemic heart disease,
hypertension, or hemodynamically insignificant va-
lvular heart disease with the exception of mitral ste-
nosis. Patients with lone AF could also be included.
Exclusion criteria
Exclusion criteria included the documented in-
effectiveness/intolerance of or contraindications to
antiarrhythmic drugs, the history of unsuccessful
cardioversion of AF, thyreotoxicosis, pregnancy or
lactation, myocardial infarction during the last
month, coronary artery bypass grafting during the
last 4 months, acute myocarditis, severe heart failu-
re (New York Heart Association functional class IV),
the history of transient ischemic attack with signi-
ficant vascular pathology requiring invasive inte-
rvention, the history of hemorrhagic stroke, ische-
mic stroke during the last 3 months, vascular heart
disease (with the exception of mitral stenosis)
requiring surgical treatment, any mitral stenosis,
severe uncontrolled hypertension (diastolic blood
pressure > 115 mm Hg), hypotension (systolic blood
pressure < 90 mm Hg), pulmonary hypertension
(tricuspid gradient > 35 mm Hg), significantly incre-
ased left atrium (short-axis diameter > 60 mm),
heart rate during AF below 90/min without rate-
controlling drugs, bundle branch block or prolon-
ged QT interval (QTc ≥ 0.45 s), significant hepatic,
renal or central nervous system dysfunction, neo-
plasm, alcohol abuse, advanced chronic obstructive
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pulmonary disease or other severe disease, contra-
indications to anticoagulation, lack of adequate co-
operation and lack of written informed consent.
Randomization and methods
Patients entering the trial were randomly as-
signed to one or two therapeutic strategies.
Randomization was performed in the coordinating
center (I Katedra i Klinika Kardiologii Akademii
Medycznej w Warszawie).
The diagnosis of AF was made upon the analysis
of a standard 12-lead electrocardiogram (ECG). In ad-
dition, 24-hour ambulatory ECG monitoring was per-
formed to confirm the chronic nature of AF and exclu-
de advanced atrioventricular conduction abnormalities.
Patients fulfilling the entry criteria were randomly as-
signed to one of the following therapeutic strategies:
— optimal ventricular rate control and anticoagu-
lation while in AF;
— restoration and maintenance of SR.
In both groups, patients were managed accor-
ding to the current clinical practice of treating per-
sistent AF [3, 4]. Details of the study protocol have
been previously described [9].
Echocardiographic studies
Transthoracic echocardiographic studies were
performed using Sonos 2000 (Hewlett-Packard),
Sequoia 256 (Acuson), and HDI 5000 (ATL) systems
with 2.5 MHz transducer. Studies were performed at
a baseline, at 2 months (in patients undergoing car-
dioversion usually 1 month after cardioversion) and
at 12 months. During an echocardiographic study,
ECG was recorded from the limb leads. Dimensions
of cardiac chambers were evaluated in the paraster-
nal long-axis view using M-mode. Measurements
were performed according to American Society of
Echocardiography conventions [10]. The following
echocardiographic parameters were evaluated: LV
end-diastolic short-axis dimension (LVEDD), LV end-
-systolic short-axis dimension (LVESD; only for the
purpose of the calculation of fractional shortening), and
LV fractional shortening (FS). All morphologic para-
meters were averaged from five measurements in
subsequent cardiac cycles.
Statistical analysis
Results for each visit are expressed as mean
values ± standard deviation (SD) for continuous
variables and numbers (percentages) for categorical
variables. A two-step analysis was used to compa-
re changes in echocardiographic parameters in the
two study groups between the baseline, 2 months,
and 12 months. ANOVA for repeated measurements
was used to determine between- and within-group
differences. If such differences were noted, compari-
sons between visits in a given group and between the
two groups for a particular visit were performed using
Student t test. Comparisons between subsequent
visits in a given group were adjusted for repeated me-
asurements. To avoid errors related to repeated com-
parisons, Bonferroni correction was applied. P < 0.05
was considered statistically significant.
Results
Study group characteristics
The study group consisted of 205 patients
(F/M 71/134; 34.6%/65.4%) aged 50–75 years (mean
age 60.8 ± 11.2 years) with persistent AF lasting
from 7 days to 2 years who were randomized to rate
versus rhythm control. Clinical characteristics and
echocardiographic parameters of LV morphology
and function in the study groups are summarized
in Table 1.
A twelve month follow-up was completed in
200 patients. Four patients (2 F, 2 M) died during
the follow-up, including two patients (1 F, 1 M) ran-
domized to the rhythm control strategy who suffe-
red a fatal massive ischemic stroke with major neu-
rological deficit, 1 female patient who died in a traf-
fic accident during the 10th month of follow-up, and
1 male patient who died due to a neoplasm. One
male patient withdrew the consent 6 months befo-
re the completion of the follow-up.
Group I — ventricular rate control
and anticoagulation in patients with AF
One hundred and one randomized patients
(F/M 38/63; mean age 61.4 ± 17.6 years), were as-
signed to the rate control approach. To control ven-
tricular rate while in AF, 8 patients (7.9%) were
given calcium antagonists (verapamil or diltiazem),
50 patients (49.5%) were given beta-blockers,
40 patients (39.6%) were given beta-blocker and
digoxin, and 3 patients (3.0%) were given only
digoxin. As anticoagulation, acenocoumarol was used
in 75 patients (74.3%), acetylsalicylic acid in 20 pa-
tients (19.8%), and ticlopidine in 1 patient (1.0%).
Five patients (4.9%) were given no anticoagulation
due to the low risk of thrombombolic complications.
Group II — SR restoration and maintenance
Elective DC cardioversion was performed in
104 patients (F/M 33/71; mean age 60.4 ± 7.9 years)
assigned to the rhythm control approach. Initial
cardioversion restored SR in 56 patients (53.8%).
In 48 patients with unsuccessful initial cardioversion,
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amiodarone was added in the overall loading dose
of 12.0 g to 16.0 g prior to another attempt of
DC cardioversion. During amiodarone loading, SR
returned in 10 patients (9.6%). The second DC car-
dioversion was performed in 38 patients, resulting
in SR restoration in another 24 patients (23.1%).
Overall, SR was restored in 90 patients (86.5%).
Subsequent DC cardioversions and the use of
antiarrhythmic drugs allowed to maintain SR during
12 months in 42 patients following initial success-
ful cardioversion and in 24 patients following suc-
cessful cardioversion preceded by amiodarone tre-
atment. Overall, SR was maintained at 12 months
in 66 patients (73.3% of all patients in whom SR was
restored) or 63.5% of all patients in Group II. Amio-
darone to prevent arrhythmia recurrence was given
at 12 months in 37 patients (56.0% of all patients in
whom SR was restored).
Effect of SR restoration and maintenance
on changes in selected echocardiographic
parameters
The dynamics of changes in echocardiographic
parameters in the two study groups during the
12-month follow-up is shown in Table 2.
Changes of LV end-diastolic dimension.
Initial evaluation using ANOVA showed significant
change in mean LVEDD during the follow-up in the
overall study group (time effect p < 0.0001, group
effect p < 0.03).
Subsequent within-group analysis showed bor-
derline significant decrease in LVEDD between
2 and 12 months in Group I (p<0.05). Borderline
significant increase in LVEDD at 2 months was fo-
und in Group II (p < 0.05). There were no signifi-
cant between-group differences throughout the fol-
low-up. The dynamics of changes in mean LVEDD
in the two study groups during the 12-month fol-
low-up is shown in Table 2 and Figure 1.
Changes in LV fractional shortening. The
initial evaluation using ANOVA showed a significant
change in mean FS during the follow-up in the ove-
rall study group (time effect p < 0.0001, interac-
tion effect p < 0.0001).
The subsequent analysis revealed modest
time-dependent increase in FS in the overall study
group. Significant increase in FS at 2 and 12 mon-
ths compared to the baseline was found in Group II
(p < 0.001). However, the latter might have resul-
ted from initially lower FS in Group II (p < 0.005).
Table 1. Clinical characteristics of the two study groups
Parameter Group I Group II
Age (years) 61.4 ± 17.6 60.4 ± 7.9
Gender:
females 38 (37.6%) 33 (31.7%)
males 63 (62.4%) 71 (68.3%)
Atrial fibrillation duration:
7 days to 1 month 17 (16.8%) 16 (15.4%)
1 month to 1 year 53 (52.4%) 73 (70.2%)
1 to 2 years 31 (30.8%) 15 (14.4%)
Mean atrial fibrillation duration (days) 243.2 ± 137.3 220.4 ± 148.6
History of paroxysmal atrial fibrillation 42 (41.6%) 37 (35.9%)
Etiology of atrial fibrillation:
ischemic heart disease 38 (37.6%) 52 (50.0%)
history of myocardial infarction 7 (6.9%) 7 (6.7%)
coronary artery bypass grafting 0 (0.0%) 1 (1.0%)
Hypertension 60 (59.4%) 72 (69.2%)
Valvular heart disease 15 (14.8%) 16 (15.4%)
Lone atrial fibrillation 25 (24.8%) 18 (17.3%)
Diabetes 18 (17.8%) 15 (14.4%)
NYHA class:
I 48 (47.5%) 30 (28.8%)
II 48 (47.5%) 59 (56.7%)
III 5 (5.0%) 15 (14.4%)
Left ventricular end-diastolic diameter [mm] 50.8 ± 5.9 52.2 ± 6.8
Fractional shortening (%) 32.8 ± 6.6 29.9 ± 6.9
There were no significant differences between groups in all tested parameters
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Figure 1. Changes in left ventricular end-diastolic dia-
meter (LVEDD) in the two study groups during the
12-month follow-up.
Figure 2. Changes in left ventricular fractional shorte-
ning (FS) in the two study groups during the 12-month
follow-up.
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There were no significant between-group differen-
ces in FS throughout the follow-up.
The dynamics of changes in mean FS in the two
study groups during the 12-month follow-up is
shown in Table 2 and Figure 2.
Discussion
Currently available knowledge regarding the
effect of AF on LV morphology and function is ba-
sed on pathophysiological considerations and the
results of small short-term unrandomized observa-
tional studies. These studies compared patients
with successful SR restoration and maintenance to
patients in whom arrhythmia termination was not
attempted or unsuccessful [11]. Most of these stu-
dies suggested benefits from SR restoration and
maintenance. Such unrandomized observational
studies are, however, subject to significant bias.
First, actual treatment intention was not accoun-
ted for and the control groups included patients with
both early and late failure of cardioversion. This
mode of comparison might also lead to another bias,
as patients in whom SR was maintained long-term
might have less advanced underlying heart disease
and thus show better parameters of LV systolic
function during long-term follow-up. Finally, lack of
randomization may also introduce significant bias.
To avoid these systematic errors, patients in
our study were randomized to rate versus rhythm
control, and the results were analyzed on an inten-
tion-to-treat basis, similarly to AFFIRM and RACE
trials, currently constituting the knowledge base
regarding the management of AF. However, the
effect of both approaches on LV function was not
a subject of direct assessment in these trials. A si-
milar rate of heart failure regardless of the assign-
ment to rate versus rhythm control may suggest
that both approaches are associated with a similar
effect on LV function.
The findings of our study confirm no significant
positive effect of the rhythm control strategy on LV
morphology and function. We found no significant
difference in LV size between the two study gro-
ups. Modest initial difference in LV size seen in
Group II at 2 months compared to the baseline se-
ems to result from slower ventricular rate following
SR restoration, leading to prolonged diastolic filling.
Table 2. Dynamics of changes in echocardiographic parameters in the two study groups during the
12-month follow-up
Parameter Follow-up p
Baseline 2 months 12 months Group Time Interaction
effect effect effect
Left ventricular Group I 50.8 ± 5.6 50.9 ± 5.7 50.0 ± 6.0 0.03 0.0001 NS
end-diastolic Group II 52.2 ± 6.8 53.4 ± 5.5 52.0 ± 7.4
diameter [mm]
Fractional Group I 32.8 ± 6.6 32.8 ± 6.7 35.6 ± 7.4 NS 0.0001 0.001
shortening (%) Group II 29.9 ± 6.9 33.3 ± 8.2 31.3 ± 7.3
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We also found no significant difference in LV sy-
stolic function between groups throughout one year
follow-up. Of note, FS increased in the overall stu-
dy group regardless of the assigned strategy, high-
lighting significant benefits resulting from the opti-
mized management of persistent AF including ade-
quate ventricular rate control and the treatment of
coexisting conditions. The negative findings of our
study may have been affected by the intention-to-
treat analysis of data. Despite the surprisingly high
effectiveness of attempts to restore and maintain
SR, AF was seen at one year in 36% of patients in
the rhythm control group.
It should be stressed that our study group se-
emed to be well representative for the average po-
pulation of patients with AF. In particular, hyper-
tension and coronary artery disease were common
in our subjects, while the advanced heart failure was
relatively rare (NYHA class III was seen in appro-
ximately 10% of patients). Of note, baseline systo-
lic LF function in the overall study group was rela-
tively preserved (mean FS 31%).
Our findings are apparently contradictory to the
reports of the effects of SR restoration in patients
with heart failure. In a study in more than 150 pa-
tients with heart failure, Okcun et al. reported si-
gnificant improvement in LV ejection fraction
(LVEF) at 1 year in patients randomized to the rhy-
thm control group [12]. French authors studied
17 patients with dilated cardiomyopathy using ra-
dionuclide ventriculography and reported increased
LVEF from 32% to 53% in 12 patients at 4 months
following successful cardioversion. In contrast,
LVEF remained unchanged in patients with unsuc-
cessful attempts to cardiovert AF, and AF recur-
rence was associated with the impairment of LV
systolic function [13]. Interesting data was recen-
tly reported by the Haissaguerre group. The abla-
tion of AF within pulmonary veins was performed
in 58 patients with symptomatic heart failure and
reduced LVEF (35%). At 12 months, SR was main-
tained in 78% of patients and an absolute increase in
LVEF by 21% was seen in these patients, both in
subjects with tachyarrhythmia-induced cardiomyopa-
thy and, albeit to a lesser extent, in patients with
heart failure resulting from other underlying struc-
tural cardiac disease [14]. Atrioventricular node abla-
tion to control ventricular rate by ventricular pacing
may also have a positive effect on LV systolic func-
tion in some patients with impaired LV function [15].
However, our study group included only few
patients with a significantly impaired LV function.
The positive effect of SR restoration on LF func-
tion in patients of heart failure may be related to
the presence of tachyarrhythmia-induced cardiomy-
opathy as the underlying or coexisting cause of
heart failure. In addition, optimal LV filling achie-
ved with atrial contraction and the lack of increased
heart rate that is commonly seen in AF may be
much more important in patients with impaired LV
systolic function than in those with preserved LV
systolic function at baseline. In the former, systo-
lic function may be improved when decompensating
factors are removed, while in the latter restoration
of SR is of less importance and has no significant
effect on LV size and systolic function.
Our findings lead to some interesting conc-
lusions. It seems that active attempts to restore
and maintain SR in patients with preserved sy-
stolic function have no effect not only on morta-
lity and thromboembolic risk, but also on LV func-
tion. This may be yet another argument in favor
of rate control approach in patients with recur-
rent AF. On the other hand, SR restoration may
be particularly beneficial in patients with under-
lying impairment of LV function. These patients
may prove difficult to maintain SR but the effect
on LV function may contribute to improved pro-
gnosis. With unfavorable long-term effectiveness
of drug treatment and promising results of non-
drug therapy, more aggressive management inc-
luding antiarrhythmic ablation should be conside-
red in these patients.
Conclusions
In an unselected group of patients with persi-
stent AF and largely preserved LV systolic func-
tion, rate control approach has no significant effect
on LV size and systolic function compared to rhy-
thm control approach.
References
1. Raymond RJ, Lee AJ, Messineo FC, Manning WJ,
Silverman DI. Cardiac performance early after
cardioversion from atrial fibrillation. Am Heart J,
1998; 136: 435–442.
2. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemo-
dynamic effects of an irregular sequence of ventricu-
lar cycle lengths during atrial fibrillation. J Am Coll
Cardiol, 1997; 30: 1039–1045.
3. Levy T, Walker S, Mason M, Spurrell P, Rex S, Brant S,
Paul V. Importance of rate control or rate regulation
for improving exercise capacity and quality of life in
patients with permanent atrial fibrillation and normal
left ventricular function: a randomised controlled
study. Heart, 2001; 85: 171–178.
337
Marcin Szulc et al., The effect of rate vs. rhythm control strategy on the LV function
www.fc.viamedica.pl
4. Upshaw CB Jr. Hemodynamic changes after cardio-
version of chronic atrial fibrillation. Arch Intern Med,
1997; 157: 1070–1076.
5. Van Gelder IC, Crijns HJ, Blanksma PK et al. Time
course of hemodynamic changes and improvement
of exercise tolerance after cardioversion of chronic
atrial fibrillation unassociated with cardiac valve dis-
ease. Am J Cardiol, 1993; 72: 560–566.
6. Dries DL, Exner DV, Gersh BJ, Domanski MJ,
Waclawiw MA, Stevenson LW. Atrial fibrillation is
associated with an increased risk for mortality and
heart failure progression in patients with asymptom-
atic and symptomatic left ventricular systolic dys-
function: a retrospective analysis of the SOLVD tri-
als. Studies of Left Ventricular Dysfunction. J Am
Coll Cardiol, 1998; 32: 695–703.
7. The Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) Investigators.
A Comparison of Rate Control and Rhythm Control
in Patients with Atrial Fibrillation. N Engl J Med,
2002; 347: 1825–1833.
8. Van Gelder IC, Hagens VE, Bosker HA et al. Rate
Control versus Electrical Cardioversion for Persis-
tent Atrial Fibrillation Study Group. A comparison of
rate control and rhythm control in patients with re-
current persistent atrial fibrillation. N Engl J Med,
2002; 347: 1834–1840.
9. Opolski G, Torbicki A, Kosior D et al. Rhythm con-
trol versus rate control in patients with persistent
atrial fibrillation. Results of the HOT CAFE Polish
Study. Kardiol Pol, 2003; 59: 1–16.
10. Report of the American Society of Echocardiography
Committee on Nomenclature and Standards in
Two-Dimentional Echocardiography. Circulation,
1980; 62: 212–228.
11. Azpitarte J, Baun O, Moreno E, Garcia-Orta R,
Sanchez-Ramos J, Tercedor L. In patients with chronic
atrial fibrillation and left ventricular systolic dysfunc-
tion, restoration of sinus rhythm confers substantial
benefit. Chest, 2001; 120: 132–138.
12. Okcun B, Yigit Z, Arat A, Kucukoglu SM. Comparison
of rate and rhythm control in patients with atrial
fibrillation and nonischemic heart failure. Jpn Heart J,
2004; 45: 591–601.
13. Kieny JR, Sacrez A, Facello A et al. Increase in radio-
nuclide left ventricular ejection fraction after cardio-
version of chronic atrial fibrillation in idiopathic di-
lated cardiomyopathy. Eur Heart J, 1992; 13: 1290–
–1295.
14. Hsu LF, Jais P, Sanders P et al. Catheter ablation for
atrial fibrillation in congestive heart failure. N Engl J
Med, 2004; 351: 2373–2383.
15. Ozcan C, Jahangir A, Friedman PA et al. Significant
effects of atrioventricular node ablation and pacemak-
er implantation on left ventricular function and long-
term survival in patients with atrial fibrillation and
left ventricular dysfunction. Am J Cardiol, 2003; 92:
33–37.
